
A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Director, Zurich, with Simon-Kucher’s Life Sciences division
A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.
Published: December 13th 2024 | Updated:
Published: June 20th 2025 | Updated: